Telomir Pharmaceuticals, Inc. Common Stock
TELO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.27 | -0.01 | -0.47 | 0.00 |
| FCF Yield | -4.17% | -1.86% | -0.23% | -0.06% |
| EV / EBITDA | 2,511.02 | -18.14 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | -1,662.28% | -111.38% | 277.16% | 737.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.31 | 0.30 | 0.55 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -31.37% | -723.58% | -292.53% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -24.43 | -0.01 | 0.00 | 0.00 |
| Interest Coverage | 2.82 | -2.40 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |